RS63061B1 - Proteini koji vezuju antigen koji aktiviraju receptor leptina - Google Patents
Proteini koji vezuju antigen koji aktiviraju receptor leptinaInfo
- Publication number
- RS63061B1 RS63061B1 RS20220294A RSP20220294A RS63061B1 RS 63061 B1 RS63061 B1 RS 63061B1 RS 20220294 A RS20220294 A RS 20220294A RS P20220294 A RSP20220294 A RS P20220294A RS 63061 B1 RS63061 B1 RS 63061B1
- Authority
- RS
- Serbia
- Prior art keywords
- antigen
- activate
- binding proteins
- leptin receptor
- leptin
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 102000005861 leptin receptors Human genes 0.000 title 1
- 108010019813 leptin receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240021P | 2015-10-12 | 2015-10-12 | |
| US201662359757P | 2016-07-08 | 2016-07-08 | |
| US201662375495P | 2016-08-16 | 2016-08-16 | |
| US201662393143P | 2016-09-12 | 2016-09-12 | |
| PCT/US2016/056465 WO2017066204A1 (en) | 2015-10-12 | 2016-10-11 | Antigen-binding proteins that activate the leptin receptor |
| EP16785072.6A EP3362477B1 (en) | 2015-10-12 | 2016-10-11 | Antigen-binding proteins that activate the leptin receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63061B1 true RS63061B1 (sr) | 2022-04-29 |
Family
ID=57184864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220294A RS63061B1 (sr) | 2015-10-12 | 2016-10-11 | Proteini koji vezuju antigen koji aktiviraju receptor leptina |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US10023644B2 (sr) |
| EP (2) | EP4071173A1 (sr) |
| JP (5) | JP7034068B2 (sr) |
| KR (1) | KR20180070609A (sr) |
| CN (1) | CN108368177B (sr) |
| AU (2) | AU2016338851B2 (sr) |
| BR (1) | BR112018007318A2 (sr) |
| CA (1) | CA3000215A1 (sr) |
| CL (2) | CL2018000946A1 (sr) |
| CO (1) | CO2018003852A2 (sr) |
| CY (1) | CY1125102T1 (sr) |
| DK (1) | DK3362477T3 (sr) |
| EA (1) | EA201890928A1 (sr) |
| ES (1) | ES2908574T3 (sr) |
| HK (1) | HK1254862A1 (sr) |
| HR (1) | HRP20220426T8 (sr) |
| HU (1) | HUE058280T2 (sr) |
| IL (2) | IL300961A (sr) |
| LT (1) | LT3362477T (sr) |
| MX (2) | MX2018004531A (sr) |
| MY (1) | MY187975A (sr) |
| PH (1) | PH12018500663A1 (sr) |
| PL (1) | PL3362477T3 (sr) |
| PT (1) | PT3362477T (sr) |
| RS (1) | RS63061B1 (sr) |
| SG (1) | SG10201913432RA (sr) |
| SI (1) | SI3362477T1 (sr) |
| TW (2) | TWI824372B (sr) |
| UA (1) | UA124419C2 (sr) |
| UY (1) | UY36942A (sr) |
| WO (1) | WO2017066204A1 (sr) |
| ZA (1) | ZA201801975B (sr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| MA45801B1 (fr) | 2016-11-08 | 2021-11-30 | Regeneron Pharma | Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine |
| MA51289A (fr) | 2017-12-18 | 2021-03-24 | Regeneron Pharma | Molécules de liaison à l'antigène bispécifiques se liant au récepteur de la leptine et/ou à gp130, et leurs procédés d'utilisation |
| MX2020010547A (es) * | 2018-04-06 | 2020-11-06 | Regeneron Pharma | Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia. |
| SG11202101638YA (en) * | 2018-10-11 | 2021-03-30 | Sumitomo Chemical Co | Propylene oxide purification system and method for producing propylene oxide |
| WO2020160199A1 (en) * | 2019-01-31 | 2020-08-06 | Siemens Healthcare Diagnostics Inc. | Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof |
| CN114391022B (zh) * | 2019-07-02 | 2023-12-12 | 上海科技大学 | 抗瘦素受体的抗体 |
| WO2021111156A1 (en) | 2019-12-03 | 2021-06-10 | Micron Technology, Inc. | Cache architecture for a storage device |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CA3192156A1 (en) * | 2020-09-15 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Use of lepr agonists for pain |
| US20240153638A1 (en) | 2021-02-22 | 2024-05-09 | Regeneron Pharmaceuticals, Inc. | Method for diagnosing and treating partial lipodystrophy |
| CN114456124B (zh) * | 2021-12-30 | 2023-04-21 | 华南农业大学 | 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US6977240B1 (en) * | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| DE69734443T2 (de) | 1996-01-08 | 2006-07-13 | Genentech, Inc., South San Francisco | Ob-rezeptor und liganden |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| EP1731164A1 (en) | 1996-01-23 | 2006-12-13 | Indevus Pharmaceuticals, Inc. | Methods for using the obese gene and its gene product to stimulate hematopoietic development |
| AUPN780096A0 (en) * | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| WO2003049673A2 (en) * | 2001-12-05 | 2003-06-19 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| JPWO2005056602A1 (ja) * | 2003-12-12 | 2008-03-06 | 中外製薬株式会社 | アゴニスト活性を有する改変抗体のスクリーニング方法 |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| US7575878B2 (en) | 2004-11-18 | 2009-08-18 | Vib Vzw | Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies |
| EP1874816A4 (en) | 2005-04-26 | 2010-08-25 | Medimmune Inc | MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| KR102426488B1 (ko) | 2012-09-12 | 2022-07-28 | 젠자임 코포레이션 | 변경된 당화 및 감소된 효과기 기능을 갖는 fc 함유 폴리펩티드 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| JP6666848B2 (ja) | 2014-02-18 | 2020-03-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｎｒｐ−１／ｏｂｒ複合体シグナル伝達経路により媒介される疾患の処置のための方法及び医薬組成物 |
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| MA51289A (fr) | 2017-12-18 | 2021-03-24 | Regeneron Pharma | Molécules de liaison à l'antigène bispécifiques se liant au récepteur de la leptine et/ou à gp130, et leurs procédés d'utilisation |
-
2016
- 2016-10-07 TW TW111100429A patent/TWI824372B/zh active
- 2016-10-07 TW TW105132493A patent/TWI752920B/zh active
- 2016-10-11 KR KR1020187013185A patent/KR20180070609A/ko not_active Application Discontinuation
- 2016-10-11 DK DK16785072.6T patent/DK3362477T3/da active
- 2016-10-11 US US15/290,967 patent/US10023644B2/en active Active
- 2016-10-11 PT PT167850726T patent/PT3362477T/pt unknown
- 2016-10-11 IL IL300961A patent/IL300961A/en unknown
- 2016-10-11 JP JP2018518592A patent/JP7034068B2/ja active Active
- 2016-10-11 CN CN201680072173.1A patent/CN108368177B/zh active Active
- 2016-10-11 SG SG10201913432RA patent/SG10201913432RA/en unknown
- 2016-10-11 UA UAA201803447A patent/UA124419C2/uk unknown
- 2016-10-11 UY UY0001036942A patent/UY36942A/es not_active Application Discontinuation
- 2016-10-11 BR BR112018007318A patent/BR112018007318A2/pt active Search and Examination
- 2016-10-11 HR HRP20220426TT patent/HRP20220426T8/hr unknown
- 2016-10-11 CA CA3000215A patent/CA3000215A1/en active Pending
- 2016-10-11 EA EA201890928A patent/EA201890928A1/ru unknown
- 2016-10-11 LT LTEPPCT/US2016/056465T patent/LT3362477T/lt unknown
- 2016-10-11 ES ES16785072T patent/ES2908574T3/es active Active
- 2016-10-11 EP EP21207469.4A patent/EP4071173A1/en active Pending
- 2016-10-11 MY MYPI2018701183A patent/MY187975A/en unknown
- 2016-10-11 WO PCT/US2016/056465 patent/WO2017066204A1/en active Application Filing
- 2016-10-11 MX MX2018004531A patent/MX2018004531A/es unknown
- 2016-10-11 HU HUE16785072A patent/HUE058280T2/hu unknown
- 2016-10-11 EP EP16785072.6A patent/EP3362477B1/en active Active
- 2016-10-11 PL PL16785072T patent/PL3362477T3/pl unknown
- 2016-10-11 SI SI201631477T patent/SI3362477T1/sl unknown
- 2016-10-11 AU AU2016338851A patent/AU2016338851B2/en active Active
- 2016-10-11 RS RS20220294A patent/RS63061B1/sr unknown
-
2018
- 2018-03-26 ZA ZA2018/01975A patent/ZA201801975B/en unknown
- 2018-03-26 PH PH12018500663A patent/PH12018500663A1/en unknown
- 2018-03-29 IL IL258448A patent/IL258448B2/en unknown
- 2018-04-11 CO CONC2018/0003852A patent/CO2018003852A2/es unknown
- 2018-04-12 CL CL2018000946A patent/CL2018000946A1/es unknown
- 2018-04-12 MX MX2023000738A patent/MX2023000738A/es unknown
- 2018-06-13 US US16/007,812 patent/US10618968B2/en active Active
- 2018-06-13 US US16/007,848 patent/US10253102B2/en active Active
- 2018-11-01 HK HK18113959.2A patent/HK1254862A1/zh unknown
-
2019
- 2019-05-28 CL CL2019001434A patent/CL2019001434A1/es unknown
- 2019-10-04 US US16/593,761 patent/US20200031946A1/en not_active Abandoned
-
2021
- 2021-03-11 JP JP2021039405A patent/JP7165225B2/ja active Active
- 2021-11-30 US US17/539,034 patent/US20220112293A1/en active Pending
-
2022
- 2022-03-31 CY CY20221100249T patent/CY1125102T1/el unknown
- 2022-10-21 JP JP2022169008A patent/JP7436603B2/ja active Active
-
2023
- 2023-07-19 AU AU2023206125A patent/AU2023206125A1/en active Pending
- 2023-11-30 JP JP2023202680A patent/JP2024026230A/ja active Pending
-
2024
- 2024-02-09 JP JP2024018406A patent/JP2024042114A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249114A1 (zh) | 針對bcma的單克隆抗體 | |
| ZA201900373B (en) | Anti-tim-3 antibodies | |
| HK1254862A1 (zh) | 激活瘦素受體的抗原結合蛋白 | |
| SG10201601719RA (en) | Anti-LAG-3 Antibodies | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| GB201610044D0 (en) | Antibodies | |
| IL272358B (en) | Antibody binding proteins that oppose the leptin receptor | |
| GB201508180D0 (en) | Antibodies | |
| GB201603291D0 (en) | Antibodies | |
| IL264262A (en) | Antibodies against interleukin 22 receptors | |
| GB201616699D0 (en) | Antibodies | |
| ZA201808317B (en) | Anti-tnfrsf25 antibodies | |
| GB201503438D0 (en) | Antibodies | |
| GB201622197D0 (en) | Antibodies | |
| GB201620414D0 (en) | Antibodies | |
| GB201615224D0 (en) | Antibodies | |
| GB201613158D0 (en) | Antibodies | |
| GB201612437D0 (en) | Anti-lag-3 antibodies | |
| GB201508437D0 (en) | Antibodies | |
| GB201507541D0 (en) | Antibodies | |
| GB201504858D0 (en) | Antibodies | |
| GB201502591D0 (en) | Antibodies |